nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.09.2009 | Original Article

Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients

verfasst von: G. Holl, R. Dorn, H. Wengenmair, D. Weckermann, J. Sciuk

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Sentinel lymph node dissection (SLND) has replaced extended lymphadenectomy for nodal staging in several solid tumours. We present our results of SLND in prostate cancer in regard to detection and false-negative rate.

Methods

In a 2-day protocol about 300 MBq ^99mTc-nanocolloid are injected into the prostate. Two hours later static scans of the pelvis are performed to get information about the number and location of radioactive lymph nodes. During surgery the radioactive nodes are excised with the help of a gamma probe and sent separately to the pathologist. The histological procedure includes haematoxylin and eosin staining, serial sections and immunohistochemistry.

Results

Since 1999, a total of 2,020 men underwent SLND alone or in combination with either standard or extended lymphadenectomy after radical retropubic prostatectomy. Lymph nodes positive for metastases were found in 16.7% of patients. The scintigraphic detection rate was 97.6% and the intraoperative detection rate 98%. For 187 lymph node-positive men who had either standard or extended lymphadenectomy in addition to SLND the false-negative rate could be calculated, resulting in false-negative findings in 11 of 187 patients (6%).

Conclusion

Our results demonstrate that SLND in prostate cancer is a reliable procedure for nodal staging.

Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–9.PubMed

Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998;339(14):941–6. doi:10.1056/NEJM199810013391401.PubMedCrossRef

Horenblas S, Jansen L, Meinhardt W, Hoefnagel CA, de Jong D, Nieweg OE. Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol 2000;163:100–4. doi:10.1016/S0022-5347(05)67982-7.PubMedCrossRef

Solsona E, Algaba F, Horenblas S, Pizzocaro G, Windahl T, European Association of Urology. EAU guidelines on penile cancer. Eur Urol 2004;46:1–8. doi:10.1016/j.eururo.2004.03.007.PubMedCrossRef

Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703–20. doi:10.1200/JCO.2005.08.001.PubMedCrossRef

Wawroschek F, Vogt H, Weckermann D, Wagner T, Harzmann R. Identifikation der Schildwächter-Lymphknoten des Prostatakarzinoms–Ergebnisse eines neuen Stagingverfahrens. Nuklearmediziner 1999;22(4):283–91.

Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Märkl B, et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003;43:132–7. doi:10.1016/S0302-2838(02)00450-5.PubMedCrossRef

Haas CJ, Wagner T, Wawroschek F, Arnholdt H. Combined application of RT-PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients. Pathol Res Pract 2005;200:763–70. doi:10.1016/j.prp. 2004.09.008.PubMedCrossRef

Wawroschek F, Vogt H, Wengenmair H, Weckermann D, Hamm M, Keil M, et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003;70:303–10. doi:10.1159/000070140.PubMedCrossRef

10.

Goppelt M, Holl G, Wagner T, Harzmann R, Weckermann D. Aussagefähigkeit der intraoperativen Schnellschnittdiagnostik der Sentinellymphknoten beim Prostatakarzinom. J Urol Urogynakol 2006;2:51.

11.

Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 2004;172:1860–4. doi:10.1097/01.ju.0000139886.25848.4a.PubMedCrossRef

12.

Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849–54. doi:10.1097/01.ju.0000049032.38743.c7.PubMedCrossRef

13.

Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:1840–4. doi:10.1097/01.ju.0000140912.45821.1d.PubMedCrossRef

14.

Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA < 10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006;50:272–9. doi:10.1016/j.eururo.2006.01.061.PubMedCrossRef

15.

Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167:1681–6. doi:10.1016/S0022-5347(05)65177-4.PubMedCrossRef

16.

Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168:514–8. doi:10.1016/S0022-5347(05)64670-8.PubMedCrossRef

17.

Kühn T, Bembenek A, Decker T, Munz DL, Sautter-Bihl ML, Untch M, et al. A concept for the clinical implementation of sentinel node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005;103:451–61. doi:10.1002/cncr.20786.CrossRef

18.

Wengenmair H, Kopp J, Vogt H, Wawroschek F, Gröber S, Dorn R, et al. Sentinel lymph node diagnosis in prostatic carcinoma: II. Biokinetics and dosimetry of 99mTc-nanocolloid after intraprostatic injection [in German]. Nuklearmedizin 2002;41:102–7.PubMed

19.

Brenot-Rossi I, Rossi D, Esterni B, Brunelle S, Chuto G, Bastide C. Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: influence of the dose of radiolabelled colloid to avoid failure of the procedure. Eur J Nucl Med Mol Imaging 2008;35:32–8. doi:10.1007/s00259-007-0516-0.PubMedCrossRef

20.

Winter A, Vogt C, Weckermann D, Harzmann R, Wawroschek F. Einfluss des Lymphdissektionsgebietes auf die Komplikationsrate der pelvinen Lymphadenektomie beim klinisch lokalisierten Prostatakarzinom. J Urol Urogynakol 2006;2:50.

21.

Winter A, Wawroschek F. Lymphadenectomy in prostate cancer. Radio-guided lymph node mapping: an adequate staging method. Front Radiat Ther Oncol 2008;41:58–67. doi:10.1159/000139879.PubMedCrossRef

22.

Jeschke S, Nambirajan T, Leeb K, Ziegerhofer J, Sega W, Janetschek G. Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2005;173:1943–6. doi:10.1097/01.ju.0000158159.16314.eb.PubMedCrossRef

Titel: Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients
verfasst von: G. Holl
R. Dorn
H. Wengenmair
D. Weckermann
J. Sciuk
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1157-2

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2009

Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment

Eugene C. Lin, Edward J. Escott, Kavita D. Garg, Andrew G. Bleicher, David Alexander: Practical differential diagnosis for CT and MRI

In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

Commentary on: Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients

68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging

[18F]Fluoroacetate is not a functional analogue of [11C]acetate in normal physiology